← 產業報告目錄
Polycystic Ovary Syndrome (PCOS) Treatment Market Size, Share & Trends Analysis Report By Drug Class (Oral Contraceptives, Insulin Sensitizing Agents, Antidepressants, Ornithine Decarboxylase Inhibitors), By Distribution Channel, By Region, And by Segment Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-03-15頁數 175報告編號 INSIGHTACE-1f7667735f
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
With a 2024 valuation of USD 4.5 Billion, the global Polycystic Ovary Syndrome (PCOS) Treatment Market is expected to surge to USD 8.0 Billion by 2034, demonstrating a CAGR of 6.1% during the 2025–2034 forecast window.
Polycystic Ovary Syndrome (PCOS) Treatment encompasses key industry insights & findings from the report:
The polycystic ovarian syndrome treatment market experienced growth due to a rise in pcos prevalence and an increase in the patient population. The sector has gained traction as organizations seek innovative approaches to address evolving healthcare challenges.
Growth is fueled by a convergence of factors: rising awareness among end users, continuous product innovation, and the escalating emphasis on efficiency and sustainability within the healthcare sector.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
From a regional perspective, mature markets in North America and Europe continue to hold notable shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and escalating investment in the sector.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Snapshot
Chapter 4. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Drug Class Estimates & Trend Analysis
5.1. by Drug Class & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Drug Class:
5.2.1. Oral Contraceptives
5.2.2. Insulin Sensitizing Agents
5.2.3. Antidepressants
5.2.4. Ornithine Decarboxylase Inhibitors
5.2.5. Aromatase Inhibitors & SERMs
5.2.6. Diuretics
Chapter 6. Market Segmentation 2: by Distribution channel Estimates & Trend Analysis
6.1. by Distribution channel & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Distribution channel:
6.2.1. Hospital Pharmacies
6.2.2. Drug Stores/OTC
6.2.3. e-Commerce
6.2.4. Clinics
Chapter 7. Polycystic Ovary Syndrome (PCOS) Treatment Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Polycystic Ovary Syndrome (PCOS) Treatment Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2021-2034
7.1.2. North America Polycystic Ovary Syndrome (PCOS) Treatment Market Revenue (US$ Million) Estimates and Forecasts by Distribution channel, 2021-2034
7.1.3. North America Polycystic Ovary Syndrome (PCOS) Treatment Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
7.2. Europe
7.2.1. Europe Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by Drug Class, 2021-2034
7.2.2. Europe Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by Distribution channel, 2021-2034
7.2.3. Europe Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by country, 2021-2034
7.3. Asia Pacific
7.3.1. Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by Drug Class, 2021-2034
7.3.2. Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by Distribution channel, 2021-2034
7.3.3. Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by country, 2021-2034
7.4. Latin America
7.4.1. Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by Drug Class, 2021-2034
7.4.2. Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by Distribution channel, 2021-2034
7.4.3. Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by country, 2021-2034
7.5. Middle East & Africa
7.5.1. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by Drug Class, 2021-2034
7.5.2. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by Distribution channel, 2021-2034
7.5.3. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by country, 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1.
8.2.2. Novartis AG
8.2.3. Sanofi
8.2.4. Teva Pharmaceutical Industries Limited
8.2.5. Merck & Co., Inc. (Merck group)
8.2.6. AstraZeneca plc.
8.2.7. Bayer AG
8.2.8. Abbott
8.2.9. Pfizer, Inc
8.2.10. Bristol-Myer Squibb Company
8.2.11. Ferring Pharmaceuticals, Inc.
8.2.12. Johnson and Johnson
8.2.13. Mylan N.V.
8.2.14. Allergan plc.
8.2.15. GlaxoSmithKline
8.2.16. Lupin Pharmaceuticals
8.2.17. AbbVie
8.2.18. Takeda
8.2.19. BIOCAD Global
8.2.20. Blairex Laboratories Inc
8.2.21. Agile Therapeutics
8.2.22. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們